Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Matthew Wood (NPI 1457359085)

Field	Value
Entity Type	Individual
Organization	Matthew Wood
Address	1710 S 70th St
City	Lincoln
State	NE
ZIP	68506
Taxonomy	Ophthalmology Physician
NPI Enumerated	July 8, 2005

Payer Source	Total Paid
Medicare	$3.9M
Medicaid	$0

Key Findings

Provider billing is effectively single–payer: this physician reports Total Medicare revenue of $3.9M and has no Medicaid billing on file, so Medicare activity drives the entire documented public-payor revenue profile. The absence of Medicaid activity means Medicaid network positioning or state-level Medicaid rate changes are unlikely to affect this provider’s billed public revenue picture directly.

Revenue is highly concentrated in a small set of expensive intravitreal drugs: the precomputed top three Medicare codes account for 83.2% of this provider’s total Medicare revenue. In particular, J2777 generated $2.1M (54.7% of Medicare revenue), J0178 generated $873.4K (22.2%), and 67028 generated $248.9K (6.3%), indicating material dependence on a narrow therapeutic mix.

Clinical/service-line implication: the dominance of J2777 and J0178 combined with procedure code 67028 signals a practice focused on intravitreal injection therapies for retinal disease (medical retina), with routine office-based injections as the primary revenue engine. The presence of retinal imaging codes such as 92134 and 92235, plus retinal surgery codes (67041, 67042, 67036) in the mix, suggests the group provides both high-volume medical retina injections and a supplement of diagnostic imaging and occasional surgical retina services.

Competitive standing for high-volume injection services is strong nationally: J2777 ranks #44 of 2039 providers nationally (98th percentile; notably above typical national volume for this code), marking this provider as a major national volume performer for faricimab administration. Similarly, 67028 ranks #92 of 4255 providers nationally (98th percentile; notably above typical national volume for this code), reinforcing that injection procedures are an outsized part of the practice relative to peers.

Other high-impact codes show mixed competitive signals: J0178 ranks #1034 of 3204 providers nationally (68th percentile; typical, unremarkable volume for this code), so aflibercept use is in line with many peers rather than dominant. Meanwhile, 99214 is flagged as an extreme outlier (2.1K claims, $181.7K revenue) and ranks #1158 of 479517 providers nationally (100th percentile; extreme outlier), indicating very high E/M volume for established patients compared with the national physician population.

Use of miscellaneous drug codes indicates additional biologic/unclassified drug billing activity: J3490 accounts for $86.9K (2.2%) and ranks #1617 of 2838 providers nationally (42th percentile; typical, unremarkable volume), while J3590 accounts for $67K (1.7%) and ranks #15 of 631 providers nationally (98th percentile; notably above typical national volume for this code). This pattern suggests non-standard biologic or buy-and-bill billing practices are present and that certain unclassified biologics are billed at rates and volumes well above most peers.

Operational and revenue risk note: with more than half of Medicare revenue coming from a single drug code (J2777 at 54.7%) and the top three codes representing 83.2% of Medicare revenue, the practice is exposed to changes in drug utilization patterns, Medicare reimbursement for these codes, or shifts in clinical guidelines. Payer negotiations and formulary/access changes that affect faricimab or aflibercept reimbursements would therefore have outsized impact on this provider’s Medicare revenue.

Tenure and practice stability: the provider’s NPI was enumerated on 2005-07-08 (~21 years ago), indicating a long-standing presence in the market. That tenure, combined with concentrated high-volume procedural and injection billing, points to an established outpatient retina practice with sustained Medicare-dependent revenue generation.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

25 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2777	Injection, faricimab‑svoa, 0.1 mg	74,040	$30	$2.1M
J0178	Injection, aflibercept, 1 mg	1,260	$690	$873.4K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	3,070	$80	$248.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,070	$90	$181.7K
J3490	Unclassified drugs	50	$1,740	$86.8K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	2,940	$30	$82.4K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	980	$80	$81.1K
J3590	Unclassified biologics	990	$70	$67K
92235	The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken…	340	$100	$33.9K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	220	$110	$23.6K

Showing 1–10 of 25

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 25 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Matthew Wood — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

25 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2777	3	10	25,950	$30	$1.5M
J0178	10	20	880	$690	$722.7K
67028	3	20	1,070	$80	$106.4K
J3590	1	10	430	$70	$29.7K
67042	9	10	30	$1,100	$29.6K
67036	3	10	30	$920	$24.9K
66821	59	80	80	$210	$23K
67108	3	10	20	$1,040	$20.8K
92014	12	270	170	$70	$20K
67041	2	10	20	$990	$18.8K

Showing 1–10 of 25

Related Providers

Other providers that share a Tax Identification Number (TIN) with Matthew Wood, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Daniel Chruscicki	NE	Ophthalmology Physician	$3M	$0
Eye Surgical Associates, LLC	NE	Ophthalmology Physician	$0	$1.7M
Gregory Sutton	NE	Ophthalmology Physician	$565.7K	$0
Jordan Rixen	NE	Ophthalmology Physician	$490.2K	$0
Vincent Sutton	NE	Ophthalmology Physician	$447.8K	$0
Samuel Thomsen	NE	Ophthalmology Physician	$428.3K	$0
Thomas Clark	NE	Ophthalmology Physician	$282.1K	$0
Thomas Graul	NE	Ophthalmology Physician	$218.6K	$0
Donald Sauberan	NE	Ophthalmology Physician	$10.9K	$0

Nearby Providers

Other providers in the same ZIP code as Matthew Wood, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bryan Medical Center	NE	General Acute Care Hospital	$0	$56.9M
Integrated Behavioral Health Services	NE	Community/Behavioral Health Agency	$0	$16.3M
Nebraska Emergency Medicine PC	NE	Emergency Medicine Physician	$0	$14.9M
Firstcare Home Health Of Eastern Nebraska, Inc	NE	Home Health Agency	$0	$6.6M
Eric Avery	NE	Hematology & Oncology Physician	$3.1M	$0
Kailash Mosalpuria	NE	Hematology & Oncology Physician	$2.9M	$0
Integrated Cardiology Group LLC	NE	Cardiovascular Disease Physician	$0	$2.7M
Madhu Midathada	NE	Hematology & Oncology Physician	$2.3M	$0
Pathology Medical Services PC	NE	Anatomic Pathology & Clinical Pathology Physician	$0	$2.1M
Rockledge Smiles LLC	NE	General Practice Dentistry	$0	$2.1M

Matthew Wood — Billing Profile & Reimbursement Data

Sign up for Matthew Wood — Billing Profile & Reimbursement Data policy alerts

Matthew Wood — Billing Profile & Reimbursement Data

Sign up for Matthew Wood — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References